Any current/future new fundraising through debt or equity?

There is no explicit mention of any current or planned fundraising through debt or equity in the discussed call transcript on pages 1-19. The company is focusing on ongoing capex of INR35-40 crores, with potential additional capex of INR50-70 crores depending on soil testing and structural design. They plan to continue aggressive capex and capacity expansion, including a greenfield plant next year. There is no indication of raising funds via debt or equity; queries about financials were directed to email contacts, but no fundraising announcement was made. The company appears to be funding cape

Any current/future capex/capital investment/strategic investment?

Ongoing capex of INR35-40 crores focused on: - New distillation facility (to be commercialized end August 2024) - Bromine recovery plant - Temporary plants for raw material and finished goods storage Additional planned capex of INR50-70 crores depending on soil test results and structural design approvals Structural engineering underway to finalize plant size (considering soil quality and possible multi-storey construction) Plans to continue aggressive capex to maximize capacity at current plant Greenfield project site launch expected next year for expansion beyond current facility Capex

Future growth expectations in sales/revenue/volumes?

SDAs segment expects ~40% volume growth, with three new large customers contributing; supply contracts discussion in October 2024 will clarify volumes. Polymer segment aims for INR 200-250 crores revenue potential in 2-3 years post-commercialization starting end of 2024. Electrolyte salts segment to see strong volume growth, with commercialization beginning early 2025 and peak around 2027, driven by hybrid battery customers. New products introduced over last two years are moving towards commercialization, enabling gradual revenue growth despite current industry headwinds. Capacity util

Future growth expectations in earnings/operating earnings/profits/EPS?

The management expects revenue growth of 20% to 30% over the next few years, driven by new product commercialization and increased volumes across segments. EBITDA margin guidance remains strong at 20% to 25% for the full year FY25 despite recent challenges. The company aims to maintain EBITDA margins between 20% to 25%, reflecting operational efficiencies. EPS is anticipated to improve inline with revenue and margin growth, though no specific EPS targets were disclosed. Growth drivers include scaling up new products in polymer and electrolyte segments, with polymer segment revenue potential es

Current/ Expected Orderbook/ Pending Orders?

The current value of the order book was not disclosed directly during the call. Management offered to provide details via email at finance@tatvachintan.com upon request. No specific figures on pending orders were shared publicly in the transcript. Demand has improved across all segments with volume growth observed. Three significant new customers were added in Q1, with supply contracts expected to be finalized by October for one large customer. Overall demand is cautiously optimistic but the industry is still running on minimum inventory levels. The management indicated improved order clarity

Tatva Chintan Pharma Chem LtdQ1 FY25Chemicals & Petrochemicals

Tatva Chintan Pharma Chem Ltd Q1 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹1,743P/E: 80.1Market Cap: ₹4.2K CrSector: Chemicals & Petrochemicals

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 2

SDAs segment expects ~40% volume growth, with three new large customers contributing; supply contracts discussion in October 2024 will clarify volumes.
Polymer segment aims for INR 200-250 crores revenue potential in 2-3 years post-commercialization starting end of 2024.
Electrolyte salts segment to see strong volume growth, with commercialization beginning early 2025 and peak around 2027, driven by hybrid battery customers.
New products introduced over last two years are moving towards commercialization, enabling gradual revenue growth despite current industry headwinds.
Capacity utilization improvement expected with reactor availability increasing post-distillation plant commissioning by August 2024; quarterly peak run rate around INR 120-130 crores.
Revenue guidance: optimistic about achieving 20%-30% growth and maintaining 20%-25% EBITDA margin in FY25.
Long-term potential revenue for select product segments estimated up to INR 650-670 crores depending on product mix.

Margin guidance

Category 3

The management expects revenue growth of 20% to 30% over the next few years, driven by new product commercialization and increased volumes across segments.
EBITDA margin guidance remains strong at 20% to 25% for the full year FY25 despite recent challenges.
The company aims to maintain EBITDA margins between 20% to 25%, reflecting operational efficiencies.
EPS is anticipated to improve inline with revenue and margin growth, though no specific EPS targets were disclosed.
Growth drivers include scaling up new products in polymer and electrolyte segments, with polymer segment revenue potential estimated around INR 200-250 crores over 2-3 years.
The electrolyte salts segment is expected to see strong volume growth from 2025 onwards as customers ramp automated battery production.
Capex plans in FY25 (INR 35-40 crores ongoing plus potential additional INR 50-70 crores) will support capacity expansion to meet growth.
Overall, management remains optimistic on medium to long term growth and profitability despite short-term industry volatility.

See what Tatva Chintan Pharma Chem Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

There is no explicit mention of any current or planned fundraising through debt or equity in the discussed call transcript on pages 1-19.
The company is focusing on ongoing capex of INR35-40 crores, with potential additional capex of INR50-70 crores depending on soil testing and structural design.
They plan to continue aggressive capex and capacity expansion, including a greenfield plant next year.
There is no indication of raising funds via debt or equity; queries about financials were directed to email contacts, but no fundraising announcement was made.
The company appears to be funding capex internally or through existing resources.

Order book

The current value of the order book was not disclosed directly during the call.
Management offered to provide details via email at finance@tatvachintan.com upon request.
No specific figures on pending orders were shared publicly in the transcript.
Demand has improved across all segments with volume growth observed.
Three significant new customers were added in Q1, with supply contracts expected to be finalized by October for one large customer.
Overall demand is cautiously optimistic but the industry is still running on minimum inventory levels.
The management indicated improved order clarity post the October meeting with the large customer, which will provide better guidance on volume contracts for the next two years.

See what Tatva Chintan Pharma Chem Ltd management said on order book — free account, 30 seconds.

Capex plans

Yes

Ongoing capex of INR35-40 crores focused on:
- New distillation facility (to be commercialized end August 2024)
- Bromine recovery plant
- Temporary plants for raw material and finished goods storage
Additional planned capex of INR50-70 crores depending on soil test results and structural design approvals
Structural engineering underway to finalize plant size (considering soil quality and possible multi-storey construction)
Plans to continue aggressive capex to maximize capacity at current plant
Greenfield project site launch expected next year for expansion beyond current facility
Capex intended to free up reactor capacity by moving recovery activities to distillation plant, improving production efficiency and capacity utilization (currently ~77%, targeting ~85% by Q3FY25)

Track Tatva Chintan Pharma Chem Ltd — get its next earnings analysis in your feed

How does Tatva Chintan Pharma Chem Ltd rank vs peers in Chemicals & Petrochemicals?

Pro feature

ThisTatva Chintan Pharma Chem Ltd

Rev 2Mar 3

See where Tatva Chintan Pharma Chem Ltd sits in Chemicals & PetrochemicalsSee which companies these are, and every other name in the sector.Open rankings

How does Tatva Chintan Pharma Chem Ltd rank in Chemicals & Petrochemicals?

Compare Tatva Chintan Pharma Chem Ltd against every Chemicals & Petrochemicals company (Q1 FY25) on revenue, margins and earnings-call signals.

View Chemicals & Petrochemicals leaderboard →

What Tatva Chintan Pharma Chem Ltd's management said in earlier quarters

Others in Chemicals & Petrochemicals this season

Prasol Chemicals Ltd (Q1 FY27)
Q1 FY27 Revenue from Operations: ₹433.6 crores . Key investor presentation takeaways from Prasol Chemicals Ltd's Q1 FY27 investor presentation — and how it rank
Vipul Organics Ltd (Q4 FY26)
Q4 FY26 (Mar 2026) total revenue: ₹5,262.37 lakhs (Consolidated) . Key concall takeaways from Vipul Organics's Q4 FY26 earnings call — and how it ranks against…
Vipul Organics Ltd (Q1 FY27)
Q1 FY27 net revenue: ₹51.78 crore, up +37.7% YoY (Page 13) . Key concall takeaways from Vipul Organics's Q1 FY27 earnings call — and how it ranks against…
Fine Organic Industries Ltd (Q1 FY27)
Revenue from Operations (Consolidated) for Q1FY27: Rs 694.2 Cr, up 18.0% YoY from Rs 588.4 Cr in Q1FY26 (Page 34). Key concall takeaways from Fine Organic…

Compare:vs Solar Industries India Ltd vs Pidilite Inds.vs SRF Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →